ArticleJCO oncology advances2025

Olaparib, Pembrolizumab, and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase II Trial.

Douglas Adkins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.